While politicians debate whether there should be federal funding of embryonic stem cells, they might be over-looking a key point: the fact that all of the momentum in stem cell research is not in cells derived from human embryos at all. Randal Mills, the chief executive officer of Osiris Therapeutics tells the Chicago Tribune's Bruce Japsen about how all of the major clinical research in the U.S. is in adult stem cells.
